April 13, 2026
Jonathan Riess, MD, MS, and Nicholas Villanueva, MD, examine the growing role of antibody-drug conjugates (ADCs) in the treatment landscape. They discuss how ADCs offer activity across heterogeneous resistance mechanisms and may serve as a bridge when targeted options are limited. The conversation also explores how prior therapies, including earlier-line intensification, may influence ADC effectiveness and sequencing decisions.
Related Posts
Future Directions: Toward Personalized EGFR Therapy in NSCLC
The Evolution of Frontline Therapy in EGFR-Mutant NSCLC
Interpreting Overall Survival Data With Combination Strategies in EGFR-Mutant NSCLC
Rethinking High-Risk EGFR-Mutant NSCLC
Integrating ctDNA Into Frontline Decision-Making in EGFR-Mutant NSCLC
